ALK and non-small cell lung carcinoma: Alectinib resulted in long‐term survival in patients with advanced ALK‐positive NSCLC, and although no OS extension was observed relative to crizotinib, it remains the standard of care for patients with advanced ALK‐positive NSCLC.